Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures

The gene expression profiles of human postmortem parietal and prefrontal cortex samples of normal controls and patients with bipolar disease, or human neuroblastoma flat (NBFL) cells treated with the mood-stabilizing drug, valproate, were used to compare the performance of Affymetrix oligonucleotide U133A GeneChips and Agilent Human 1 cDNA microarrays. Among those genes represented on both platforms, the oligo array identified 26-53% more differentially expressed genes compared to the cDNA array in the three experiments, when identical fold change and t-test criteria were applied. The increased sensitivity was primarily the result of more robust fold changes measured by the oligonucleotide system. Essentially all gene changes overlapping between the two platforms were co-directional, and ranged from 4 to 19% depending upon the amount of biological variability within and between the comparison groups. Q-PCR validation rates were virtually identical for the two platforms, with 23-24% validation in the prefrontal cortex experiment, and 56% for both platforms in the cell culture experiment. Validated genes included dopa decarboxylase, dopamine beta-hydroxylase, and dihydropyrimidinase-related protein 3, which were decreased in NBFL cells exposed to valproate, and spinocerebellar ataxia 7, which was increased in bipolar disease. The modest overlap but similar validation rates show that each microarray system identifies a unique set of differentially expressed genes, and thus the greatest information is obtained from the use of both platforms.

[1]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[2]  M. Owen,et al.  Genome scans and microarrays: converging on genes for schizophrenia? , 2002, Genome Biology.

[3]  R. Yolken,et al.  The Stanley Foundation brain collection and Neuropathology Consortium , 2000, Schizophrenia Research.

[4]  S. Sealfon,et al.  Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. , 2002, Nucleic acids research.

[5]  T. G. Bruun,et al.  Two novel variants in the DOPA decarboxylase gene: association with bipolar affective disorder , 1999, Molecular Psychiatry.

[6]  M. Webster,et al.  Application of cDNA microarrays to examine gene expression differences in schizophrenia , 2001, Brain Research Bulletin.

[7]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[8]  R. Nuttall,et al.  An evaluation of the performance of cDNA microarrays for detecting changes in global mRNA expression. , 2001, Nucleic acids research.

[9]  M. Nonaka,et al.  A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. , 1996, Gene.

[10]  M. Hampson,et al.  Dopa decarboxylase genotypes may influence age at onset of schizophrenia , 2001, Molecular Psychiatry.

[11]  Wei Zhang,et al.  Obtaining reliable information from minute amounts of RNA using cDNA microarrays , 2002, BMC Genomics.

[12]  John Quackenbush.  Microarray data normalization and transformation , 2002, Nature Genetics.

[13]  W. Rychlik,et al.  Selection of primers for polymerase chain reaction , 1995, Molecular biotechnology.

[14]  Johan T den Dunnen,et al.  A common reference for cDNA microarray hybridizations. , 2002, Nucleic acids research.

[15]  S. McElroy,et al.  Valproatereatment of Acute Mania: A Placebo-Controlled , 1991 .

[16]  K. Kaibuchi,et al.  CRMP-2 induces axons in cultured hippocampal neurons , 2001, Nature Neuroscience.

[17]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Edwin J. Weeber,et al.  SCA7 Knockin Mice Model Human SCA7 and Reveal Gradual Accumulation of Mutant Ataxin-7 in Neurons and Abnormalities in Short-Term Plasticity , 2003, Neuron.

[19]  R. Nadon,et al.  Statistical issues with microarrays: processing and analysis. , 2002, Trends in genetics : TIG.

[20]  T. Nagasu,et al.  Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. , 2001, Brain research. Gene expression patterns.

[21]  Huda Akil,et al.  Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. , 2004, Human molecular genetics.

[22]  M. Owen,et al.  Long repeat tracts at SCA8 in major psychosis. , 2000, American journal of medical genetics.

[23]  Y. Agid,et al.  Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion , 1997, Nature Genetics.

[24]  Alan C. Evans,et al.  Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  K. Burns,et al.  Expression profiling analyses of gonadotropin responses and tumor development in the absence of inhibins. , 2003, Endocrinology.

[26]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. G. Standaert,et al.  Gene expression profiling in the post-mortem human brain — no cause for dismay , 2001, Journal of Chemical Neuroanatomy.

[28]  R. Lempicki,et al.  Evaluation of gene expression measurements from commercial microarray platforms. , 2003, Nucleic acids research.

[29]  D. Collier,et al.  Possible parent‐of‐origin effect of Dopa decarboxylase in susceptibility to bipolar affective disorder , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[30]  C. Ramchand,et al.  Is the polymorphic microsatellite repeat of the dopamine β-hydroxylase gene associated with biochemical variability of the catecholamine pathway in schizophrenia? , 1997, Biological Psychiatry.

[31]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Barrette,et al.  Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. , 2002, Cancer research.

[33]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[34]  S K Libutti,et al.  Advantages of mRNA amplification for microarray analysis. , 2002, BioTechniques.

[35]  Jerry Li,et al.  Within the fold: assessing differential expression measures and reproducibility in microarray assays , 2002, Genome Biology.

[36]  Huda Akil,et al.  Microarray technology: a review of new strategies to discover candidate vulnerability genes in psychiatric disorders. , 2003, The American journal of psychiatry.

[37]  C. Duyckaerts,et al.  Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3. , 2001, Human molecular genetics.

[38]  Jun-Feng Wang,et al.  Gene expression differences in bipolar disorder revealed by cDNA array analysis of post‐mortem frontal cortex , 2001, Journal of neurochemistry.

[39]  Ravi Kothapalli,et al.  Microarray results: how accurate are they? , 2002, BMC Bioinformatics.

[40]  S. Suzuki,et al.  An autopsy case of spinocerebellar ataxia type 6 with mental symptoms of schizophrenia and dementia. , 1999, Clinical neuropathology.

[41]  L. Nisenbaum.  The ultimate chip shot: can microarray technology deliver for neuroscience? , 2002, Genes, brain, and behavior.

[42]  Nigel J. Walker,et al.  A Technique Whose Time Has Come , 2002, Science.

[43]  C. Ramchand,et al.  A study of the relationship between the DBH activity in serum and a MspI polymorphic site in intron 9 of the human DBH gene in schizophrenia , 1996, Schizophrenia Research.

[44]  P. van Hummelen,et al.  Production of bulk amounts of universal RNA for DNA microarrays. , 2002, BioTechniques.

[45]  M. Rajeevan,et al.  Use of real-time quantitative PCR to validate the results of cDNA array and differential display PCR technologies. , 2001, Methods.

[46]  Andrew Lemire,et al.  Electroconvulsive Seizures Regulate Gene Expression of Distinct Neurotrophic Signaling Pathways , 2004, The Journal of Neuroscience.

[47]  Stephen M. Hewitt,et al.  Post-analysis follow-up and validation of microarray experiments , 2002, Nature Genetics.

[48]  J. Pierri,et al.  Gene Expression Profiling Reveals Alterations of Specific Metabolic Pathways in Schizophrenia , 2002, The Journal of Neuroscience.

[49]  Lucila Ohno-Machado,et al.  Analysis of matched mRNA measurements from two different microarray technologies , 2002, Bioinform..

[50]  C. Holtzer,et al.  Valproate in the Treatment of Acute Mania , 1996 .

[51]  Kenji Yamamoto,et al.  Dopamine Beta‐Hydroxylase (DBH) gene and schizophrenia phenotypic variability: A genetic association study , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[52]  R. Yolken,et al.  Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder , 2000, Molecular Psychiatry.

[53]  J. Calabrese,et al.  Relation of serum valproate concentration to response in mania. , 1996, The American journal of psychiatry.

[54]  C. Altar,et al.  Novel directions in antipsychotic target identification using gene arrays. , 2002, Current drug targets. CNS and neurological disorders.

[55]  Tyrone D. Cannon,et al.  Possible association between schizophrenia and a CAG repeat polymorphism in the spinocerebellar ataxia type 1 (SCA1) gene on human chromosome 6p23. , 1999, Psychiatric genetics.

[56]  T. Hastie,et al.  Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis , 2002, BMC Genomics.